Home » Topics » BioWorld Science

BioWorld Science
RSS

ABO-102 demonstrates evidence of clinical benefit in patients with MPS IIIA

Feb. 18, 2021

vTv initiates phase I study of PDE4 inhibitor HPP-737 for psoriasis

Feb. 18, 2021

SciSparc signs agreement for phase IIa trial of SCI-110 for Alzheimer agitation

Feb. 18, 2021

Study may yield ways to harness bacterial antibiotic production

Feb. 18, 2021

AbFero receives funding for development of SP-420 for Parkinson's disease

Feb. 18, 2021

First patient dosed in U.S. phase II/III COVID-19 outpatient study of RHB-107

Feb. 18, 2021

N-803 plus BCG shows promise for treating NMIBC

Feb. 18, 2021

Highly phosphorylated GCase M-011 exhibits improved potential in Gaucher disease

Feb. 18, 2021

First patient dosed in phase I study of IkT-148009

Feb. 18, 2021

New anoctamin-1 potentiators synthesized at Enterprise Therapeutics

Feb. 18, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...